AlenCiken

Marinus Announces Successful Clinical Trial Results

NASDAQ:MRNS   Marinus Pharmaceuticals, Inc.
top-line data from the Phase 2 open-label study in patients with CDKL5 disorder support advancing ganaxolone into a definitive late-stage clinical trial.

globenewswire.com/ne...-for-Ganaxolone.html


Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.